Targeted therapies: other agents

[1]  M. Dougados,et al.  Rituximab Treatment for Spondyloarthritis. A Nationwide Series: Data from the AIR Registry of the French Society of Rheumatology , 2012, The Journal of Rheumatology.

[2]  R. Bruckert,et al.  Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study , 2012, Arthritis Research & Therapy.

[3]  R. Bruckert,et al.  Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. , 2012, Joint, bone, spine : revue du rhumatisme.

[4]  C. Prati,et al.  Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonists. , 2011, Joint, bone, spine : revue du rhumatisme.

[5]  J. Braun,et al.  Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study , 2011, Annals of the rheumatic diseases.

[6]  Y. Shima,et al.  Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis , 2011, Modern rheumatology.

[7]  C. Prati,et al.  Short-term effect of IL-6 inhibition in spondylarthritis. , 2010, Joint, bone, spine : revue du rhumatisme.

[8]  C. Gabay,et al.  Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. , 2010, Joint, bone, spine : revue du rhumatisme.

[9]  L. Kanz,et al.  Mixed response to tocilizumab for ankylosing spondylitis , 2010, Annals of the rheumatic diseases.

[10]  J. Braun,et al.  Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. , 2010, Arthritis and rheumatism.

[11]  D. Wendling.  Interleukin‐6 as a therapeutic target in spondylarthritis: Comment on the article by Tanaka et al , 2010, Arthritis care & research.

[12]  D. Wendling.  IL-23 and IL-17 in ankylosing spondylitis , 2010, Rheumatology International.

[13]  A. Gottlieb,et al.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2009, The Lancet.

[14]  J. Listing,et al.  Open label trial of anakinra in active ankylosing spondylitis over 24 weeks , 2004, Annals of the rheumatic diseases.

[15]  Alexander M. Fraser,et al.  Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study , 2004, Annals of the rheumatic diseases.